CML patients can benefit from imatinib after unsuccessful interferon therapies A fresh study has found that individuals with chronic myeloid leukemia who’ve not taken care of immediately interferon treatments experience long-term benefits when they change to the targeted medication imatinib. Published early online in Malignancy, a peer-reviewed journal of the American Cancer tumor Society, the scholarly research indicates that imatinib is the treatment of preference for these patients http://le-priligy.com/levitra-et-dapoxetine/ . Imatinib, a drug that blocks the protein made by a specific cancer-causing gene, has revolutionized the treatment and prognosis of individuals with CML.
This announcement comes as the ATA, the biggest international tradeshow centered on telemedicine exclusively, telehealth, and remote control medical technologies, occurs on, may 1st-3rd, 2011 in Tampa, Florida. This difficult-to-miss screen of state-of-the-art technology will include a free coffee bar also, and 30 percent discounts on every system acquired in this tradeshow. Sevrain, CJPS Medical System’s LEADER.